News

Effectiveness of ESAs in treating anaemia in kidney disease and cancer patients

Published on 2017/03/31

Erythropoiesis-stimulating agents (ESAs) are biological analogues of human erythropoietin used for the treatment of anaemia associated with chronic kidney disease (CKD) and chemotherapy treatment ...

54 views

Read more →

Switching between generics of anti-epileptic drugs

Published on 2017/03/29

Two different generic versions of anti-epilepsy medicine lamotrigine have been shown to be bioequivalent in patients with epilepsy and to not cause any differences in seizure frequency or adverse ...

52 views

Read more →

Monoclonal antibodies and the challenge of substitution

Published on 2017/03/27

Healthcare payers are eagerly awaiting the arrival of biosimilar competition in the innovative monoclonal antibody sector in order to drive down drug prices and increase patients’ access to thes...

27 views

Read more →

South Korean pharma market to reach US$20 billion by 2020

Published on 2017/03/24

The pharmaceutical market in South Korea is on the increase and is expected to reach more than US$20 billion by 2020. According to a report by research and consulting firm GlobalData, the...

316 views

Read more →

Cost-effectiveness analysis and incentivizing innovation

Published on 2017/03/22

In the paper by Santiago Moreno and Joshua Ray, the controversial role that conventional cost-effectiveness analysis (CEA) plays in incentivizing innovation is revealed [1]. Detractors criticize i...

48 views

Read more →

Is a new pathway for NBCDs on the way in the US?

Published on 2017/03/20

The US Food and Drug Administration (FDA) does not formerly recognize non-biological complex drugs (NBCDs), with originators required to follow the new drug application (NDA) route and follow-on N...

43 views

Read more →

Switching between different ESAs

Published on 2017/03/17

Switching between reference biologicals and biosimilars can be a contentious issue. A study from Italy, however, has found that this phenomenon is not limited to reference products and their biosi...

40 views

Read more →

Japan proving to be a favourable market for biosimilars

Published on 2017/03/15

Uptake of biosimilars in Japan is on a par with generics use for some products, making Japan a lucrative market for biosimilars makers. In Japan, the biosimilars guidelines, based on the ...

125 views

Read more →

Perceptions of the value of generics in Brazil

Published on 2017/03/13

Generics were first approved in Brazil in 1999. Substitution of generics and reference drugs can occur at the time of purchase and upon patients’ request, and, in the public healthcare system, p...

115 views

Read more →

Clinical and regulatory issues for biosimilars

Published on 2017/03/10

As the first biosimilars are being approved in the US, there are a number of clinical and regulatory issues that must be considered for the safe and appropriate utilization of these products withi...

60 views

Read more →

Perceptions of the effectiveness and quality of generics

Published on 2017/03/08

More than a quarter of doctors and the general public believe that generics are less effective and of poorer quality than brand-name drugs, according to a study carried out by researchers from New...

98 views

Read more →

A strategic approach to increase uptake of biosimilars in Spain

Published on 2017/03/06

Ainhoa Aranguren Oyarzábal and colleagues from the Madrid Health Service (MHS), Spain, describe the strategic approach that has been introduced in Spain to try and improve uptake of biosimilars i...

86 views

Read more →